中恒集团(600252.SH)：控股子公司获得药品注册证书

Core Insights - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two drugs: Nicardipine Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) [1] Group 1 - The approval of Nicardipine Tablets and Ketorolac Tromethamine Injection is expected to enhance the company's product line [1]